- CAR-iNKT construct avidity profiled and ranked under physiological shear conditions
- Avidity profiles shown to mirror in vivo survival outcomes
- High-avidity fractions enriched for superior CAR surface expression and functional quality
- Mechanistic insight beyond conventional static in vitro assays
- Predictive, cost-efficient approach enabling confident CAR construct selection and de-risked preclinical translation
CAR-iNKT therapies are a promising class of cell-based immunotherapy, bridging adaptive antigen recognition with innate effector behaviour. However, their development remains slow and high risk, in part because existing static in vitro assays provide limited insight into immune-tumour engagement. Efficacy and clinical suitability remain unclear until animal studies, where failures are costly and detrimental. The absence of predictive, dynamic in vitro assays remains a critical bottleneck to accelerating and de-risking CAR-iNKT development.
We applied our avidity-based microfluidic platform to holistically quantify CAR-iNKT tumour cell engagement under dynamic, cell-based conditions, capturing the integrated strength and stability of immune-target interactions that underpin efficacy and safety. Multiple CAR-iNKT constructs were profiled alongside a non-transduced control and validated against in vivo MM1.S mouse tumour models, enabling direct correlation between preclinical avidity data and therapeutic outcome.
- Quantified CAR-iNKT binding strength under controlled physiological flow conditions
- Profiled and ranked multiple constructs head-to-head alongside non-transduced control
- Separated high- and low-avidity cell populations with clean CAR-expressing cell enrichment
- Correlated in vitro avidity profiles directly with in vivo tumour control and survival
- Delivered predictive functional insight beyond conventional static assays
in high-avidity cell fractions
We applied our avidity-based microfluidic platform to holistically quantify CAR-iNKT tumour cell engagement under dynamic, cell-based conditions, capturing the integrated strength and stability of immune-target interactions that underpin efficacy and safety. Multiple CAR-iNKT constructs were profiled alongside a non-transduced control and validated against in vivo MM1.S mouse tumour models, enabling direct correlation between preclinical avidity data and therapeutic outcome.
- Quantified CAR-iNKT binding strength under controlled physiological flow conditions
- Profiled and ranked multiple constructs head-to-head alongside non-transduced control
- Separated high- and low-avidity cell populations with clean CAR-expressing cell enrichment
- Correlated in vitro avidity profiles directly with in vivo tumour control and survival
- Delivered predictive functional insight beyond conventional static assays
in high-avidity cell fractions
in high-avidity cell fractions
By measuring cellular avidity under dynamic, physiologically relevant conditions, we accurately ranked CAR-iNKT construct performance and predicted in vivo efficacy before animal studies. Avidity profiles directly mirrored tumour control and survival outcomes, while high-avidity fractions showed approximately ten-fold greater CAR surface density than low-avidity counterparts. These findings demonstrate how our platform enables early, functionally driven selection of superior CAR constructs, supporting confident and de-risked preclinical decision-making and reducing reliance on costly animal studies.
